| Literature DB >> 31604413 |
Md Tanvir Kabir1, Mohammad A Sufian2, Md Sahab Uddin3,4, Mst Marium Begum2, Shammi Akhter3, Ariful Islam5, Bijo Mathew6, Md Siddiqul Islam3, Md Shah Amran7, Ghulam Md Ashraf8,9.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease that causes problems with memory, thinking, and behavior. Currently, there is no drug that can reduce the pathological events of this degenerative disease but symptomatic relief is possible that can abate the disease condition. N-methyl-D-aspartate (NMDA) receptors exert a critical role for synaptic plasticity as well as transmission. Overstimulation of glutamate receptors, predominantly NMDA type, may cause excitotoxic effects on neurons and is recommended as a mechanism for neurodegeneration. Atypical activation of the NMDA receptor has been suggested for AD by synaptic dysfunction. NMDA receptor antagonists especially memantine block the NMDA receptor and can reduce the influx of calcium (Ca2+) ions into neuron, thus, toxic intracellular events are not activated. This review represents the role of NMDA receptors antagonists as potential therapeutic agents to reduce AD. Moreover, this review highlights the repositioning of memantine as a potential novel therapeutic multitargeting agent for AD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Alzheimer’s disease; NMDA antagonists; amyloid beta; glutamate receptors; memantine; tau.
Mesh：
Substances：
Year: 2019 PMID： 31604413 DOI： 10.2174/1381612825666191011102444
Source DB: PubMed Journal: Curr Pharm Des ISSN： 1381-6128 Impact factor: 3.116